Petros Pharmaceuticals (PTPI) Competitors

$0.0061 0.00 (0.00%)

As of 05/22/2026 02:02 PM Eastern

PTPI vs. CNSP, WINT, PTIX, ASBP, and CMND

Should you buy Petros Pharmaceuticals stock or one of its competitors? MarketBeat compares Petros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Petros Pharmaceuticals include CNS Pharmaceuticals (CNSP), Windtree Therapeutics (WINT), Atrinsic (PTIX), Aspire Biopharma (ASBP), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.98 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Positive

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 269.00%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Petros Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Summary

Petros Pharmaceuticals and CNS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Petros Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Windtree Therapeutics	N/A	-207.34%	-50.19%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Windtree Therapeutics	Neutral

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Windtree Therapeutics has lower revenue, but higher earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A

Summary

Petros Pharmaceuticals beats Windtree Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Atrinsic?

Petros Pharmaceuticals (NASDAQ:PTPI) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Atrinsic has lower revenue, but higher earnings than Petros Pharmaceuticals. Atrinsic is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Atrinsic	N/A	N/A	-379.72%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Atrinsic	Neutral

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 8.0% of Atrinsic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Petros Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Atrinsic on 7 of the 10 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Aspire Biopharma?

Petros Pharmaceuticals (NASDAQ:PTPI) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Petros Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Aspire Biopharma	$10K	703.30	-$24.48M	-$116.67	N/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Aspire Biopharma	Neutral

Aspire Biopharma's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Aspire Biopharma	N/A	N/A	-398.04%

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Petros Pharmaceuticals beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, Clearmind Medicine had 6 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 6 mentions for Clearmind Medicine and 0 mentions for Petros Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.24 beat Petros Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Clearmind Medicine	Neutral
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals' return on equity of -78.22% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-207.53%	-100.70%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Clearmind Medicine has higher earnings, but lower revenue than Petros Pharmaceuticals. Clearmind Medicine is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$19.72	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A

Summary

Petros Pharmaceuticals beats Clearmind Medicine on 7 of the 11 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$190K	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	0.00	1.46	20.99	25.66
Price / Sales	0.04	119.63	559.58	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	0.00	7.59	10.44	7.14
Net Income	-$8.16M	-$3.64M	$3.57B	$335.98M
7 Day Performance	N/A	3.01%	6.37%	4.11%
1 Month Performance	N/A	76.62%	3.51%	2.52%
1 Year Performance	N/A	126.61%	34.10%	35.04%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-84.4%	$190K	$5.11M	N/A	20	Gap Up
CNSP CNS Pharmaceuticals	3.7911 of 5 stars	$5.52 -9.8%	$20.00 +262.3%	-58.9%	$4.47M	N/A	N/A	5
WINT Windtree Therapeutics	N/A	$0.02 +6.4%	N/A	-98.2%	$895K	N/A	N/A	30	Gap Down
PTIX Atrinsic	N/A	$0.49 +1.2%	N/A	-87.0%	$887K	N/A	N/A	2
ASBP Aspire Biopharma	0.1521 of 5 stars	$5.30 +2.5%	N/A	N/A	$885K	$6.20K	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, WINT, PTIX, ASBP, and CMND

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Summary

How does Petros Pharmaceuticals compare to Atrinsic?

Summary

How does Petros Pharmaceuticals compare to Aspire Biopharma?

Summary

How does Petros Pharmaceuticals compare to Clearmind Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, WINT, PTIX, ASBP, and CMND

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Does the media refer more to PTPI or CNSP?

Which has stronger valuation & earnings, PTPI or CNSP?

Do analysts recommend PTPI or CNSP?

Do insiders and institutionals have more ownership in PTPI or CNSP?

Which has more volatility and risk, PTPI or CNSP?

Is PTPI or CNSP more profitable?

Summary

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Which has more volatility and risk, PTPI or WINT?

Is PTPI or WINT more profitable?

Does the media refer more to PTPI or WINT?

Do insiders & institutionals have more ownership in PTPI or WINT?

Which has higher valuation & earnings, PTPI or WINT?

Summary

How does Petros Pharmaceuticals compare to Atrinsic?

Which has preferable valuation and earnings, PTPI or PTIX?

Do analysts rate PTPI or PTIX?

Is PTPI or PTIX more profitable?

Does the media refer more to PTPI or PTIX?

Do institutionals and insiders have more ownership in PTPI or PTIX?

Which has more volatility and risk, PTPI or PTIX?

Summary

How does Petros Pharmaceuticals compare to Aspire Biopharma?

Which has more volatility and risk, PTPI or ASBP?

Which has stronger earnings & valuation, PTPI or ASBP?

Does the media prefer PTPI or ASBP?

Is PTPI or ASBP more profitable?

Do insiders & institutionals hold more shares of PTPI or ASBP?

Do analysts rate PTPI or ASBP?

Summary

How does Petros Pharmaceuticals compare to Clearmind Medicine?

Which has more volatility & risk, CMND or PTPI?

Does the media refer more to CMND or PTPI?

Is CMND or PTPI more profitable?

Do insiders & institutionals have more ownership in CMND or PTPI?

Which has better earnings & valuation, CMND or PTPI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools